Produktinformation
- 1-(2-Ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole
- 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazole
- 1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)[1,4]diazepane
- 1-[2-(Ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
- 1H-1,4-Diazepine, 1H-benzimidazole deriv.
- 1H-benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-
- 87233-61-2
- Rapimine
Emedastine is a non-sedating antihistamine that blocks the action of histamines in the body. It inhibits the release of inflammatory substances, such as eosinophil cationic protein and leukotrienes, from cells. Emedastine also has been shown to inhibit the activity of 2-adrenergic receptors in vitro and in vivo. This drug has been shown to have long-term efficacy in humans and has a favorable side effect profile. It is also effective for treating allergic rhinitis, but not asthma or chronic urticaria. Emedastine is metabolized by cytochrome P450 enzymes, followed by metabolism by glucuronidases or esterases. The antihistamine can be detected in human serum up to 24 hours after oral administration, with peak concentrations reached within 1 hour.
Emedastine has been shown to be an effective treatment for allergic rhinitis and
has a favorable side-effect
